lifitegrast
Selected indexed studies
- Lifitegrast. (, 2006) [PMID:29999933]
- Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). (Ophthalmology, 2017) [PMID:28079022]
- Lifitegrast: a novel drug for patients with dry eye disease. (Ther Adv Ophthalmol, 2019) [PMID:31489402]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lifitegrast. (2006) pubmed
- Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). (2017) pubmed
- Lifitegrast: a novel drug for patients with dry eye disease. (2019) pubmed
- Lifitegrast in Treatment of Dry Eye Disease-A Practical, Narrative Expert Review. (2025) pubmed
- Lifitegrast for the treatment of dry eye disease in adults. (2017) pubmed
- Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis. (2022) pubmed
- Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease. (2017) pubmed
- Lifitegrast, Bezlotoxumab, and Sugammadex sodium. (2017) pubmed
- Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program. (2019) pubmed
- Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology. (2026) pubmed